MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Personalis Operating Cycle 2011-2026 | PSNL
Annual Operating Cycle Personalis
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55.8 | 85.4 | 98.5 | 53 | 22.4 | 30.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98.5 | 22.4 | 57.6 |
Quarterly Operating Cycle Personalis
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 76.6 | 55.5 | 42.3 | - | 46.8 | 49 | 67.9 | - | 59.5 | 77.1 | 84 | - | 41.7 | 33.8 | 95.8 | - | 40.6 | 36.5 | 31.5 | - | 29.2 | 29.7 | 23 | 16.6 | 17.6 | 19 | 25.1 | 30.9 | 34.9 | 23.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 95.8 | 16.6 | 43.5 |
Operating Cycle of other stocks in the Diagnostics research industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
161 | $ 110.24 | -2.86 % | $ 33.5 B |  USA |
 |
Centogene N.V.
CNTG
|
170 | - | -6.23 % | $ 30.6 M |  Germany |
 |
Waters Corporation
WAT
|
834 | $ 289.16 | -3.79 % | $ 17.2 B | USA |
 |
Exagen
XGN
|
51.2 | $ 2.68 | -3.94 % | $ 57.8 M | USA |
 |
Enzo Biochem
ENZ
|
206 | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
91.7 | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
57.4 | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
275 | $ 16.36 | -11.57 % | $ 176 M |  China |
 |
Sotera Health Company
SHC
|
80.3 | $ 13.13 | -3.03 % | $ 3.73 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
89 | $ 26.78 | -1.33 % | $ 20 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
68.5 | $ 102.08 | -0.97 % | $ 8.42 B |  Irlanda |
 |
Heska Corporation
HSKA
|
177 | - | - | $ 1.31 B | USA |
 |
BioNano Genomics
BNGO
|
315 | $ 1.16 | 0.87 % | $ 6.32 M | USA |
 |
DermTech
DMTK
|
114 | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
73.8 | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
202 | $ 62.25 | -5.81 % | $ 24.3 B | USA |
 |
Accelerate Diagnostics
AXDX
|
489 | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
202 | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
11.8 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
185 | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
216 | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
97.9 | $ 23.53 | -4.74 % | $ 654 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.22 K | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
65 | $ 159.16 | -3.62 % | $ 7.89 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
54.2 | $ 195.51 | -1.33 % | $ 21.7 B | USA |
 |
Organovo Holdings
ONVO
|
79.8 | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M | USA |
 |
Biocept
BIOC
|
134 | - | -13.05 % | $ 7.29 M | USA |
 |
PerkinElmer
PKI
|
92.2 | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
368 | - | - | $ 21.2 M | USA |
 |
Interpace Biosciences
IDXG
|
79.2 | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K |  Israel |
 |
QIAGEN N.V.
QGEN
|
172 | - | - | $ 10.6 B | Niderland |
 |
Neogen Corporation
NEOG
|
213 | $ 8.7 | -4.92 % | $ 1.89 B | USA |
 |
Chembio Diagnostics
CEMI
|
164 | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
71.8 | $ 264.2 | -1.56 % | $ 22 B | USA |
 |
Psychemedics Corporation
PMD
|
61.3 | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
49.8 | $ 25.97 | -4.52 % | $ 33.7 M | USA |
 |
CareDx, Inc
CDNA
|
51.5 | $ 16.78 | -3.95 % | $ 894 M | USA |
 |
Quotient Limited
QTNT
|
432 | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Syneos Health
SYNH
|
102 | - | - | $ 4.46 B | USA |
 |
Renalytix AI plc
RNLX
|
15.9 | - | 5.66 % | $ 22.7 M |  Britain |
 |
VolitionRx Limited
VNRX
|
52.3 | $ 0.2 | 1.87 % | $ 19.2 M |  Singapore |
 |
Bioventus
BVS
|
259 | $ 8.94 | -3.46 % | $ 596 M | USA |
 |
Co-Diagnostics
CODX
|
405 | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Meridian Bioscience
VIVO
|
238 | - | - | $ 1.49 B | USA |
 |
Danaher Corporation
DHR
|
143 | $ 181.52 | -3.27 % | $ 129 B | USA |